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Abstract 
Particles for subcutaneous depot use encapsulating a model water soluble 
drug have been produced from poly(lactic-glycolic acid) (PLGA) using a 
membrane emulsification – solvent evaporation technique. The release 
behaviour, mainly the change in size and inner morphology are reported. 
During release, the particles initially swelled in size, then reduced. A diffusion 
based model, taking in to account the change in particle size, is presented. 
Surface erosion is evident from the particle size and image evidence, and the 
diffusion model provides a fit to the data even during the surface erosion 
period, suggesting that the model drug diffuses before the particle degrades. 
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Introduction 
A comprehensively studied field in the pharmaceutical sector is controlled 
drug release from biodegradable polymer matrixes. Numerous researchers 
have focused on production of nanoparticles, which can be used for very fine 
spray inhalators, or intravenous injections. Larger particles, between 5 and 
150 micrometres, are useful because they are large enough to remain at the 
site of injection and provide significant drug loading, but small enough to be 
administered through a relatively small-gauge hypodermic needle. This work 
used poly(d,l-lactide-glicolide acid), or PLGA, because of its versatility, 
availability, and well-known suitability as a controlled release biocompatible 
polymer. 
The PLGA particles were produced by membrane emulsification followed by 
solvent evaporation and the membrane emulsification method followed here 
has been thoroughly described previously [1-5]. Specifically, its application for 
PLGA particle production has been reported [6], from which this work follows. 
For the emulsification step, other methods are available, such as: 
homogenizer, sonication [7-9] and stirring [10-14]. These are straightforward 
techniques, but it is difficult to control the size and size distribution of the 
drops. The SPG glass membrane [15-17] and vibrating nozzle [18-22] provide 
better control of size. 
Building on the previous work [6], a range of monosized particles containing a 
water soluble model drug with high encapsulation efficiency were produced 
and exposed to release conditions in way not normally reported. Because of 
the relatively high quantity of particles produced, by employing the lamina 
surface membrane emulsification technique, it was possible to divide the 
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particles in to ten independent samples, which were subjected to identical 
model drug release conditions. At regular intervals, one sample was analyzed 
while the others continued undisturbed. Not only the water medium was 
analyzed, but also the particles were tested and disposed of without disturbing 
the remaining particles under test. Results from the change in size of the 
particles during release are shown and a release model based on diffusion 
coupled to particle size change is proposed. In other studies, PLGA may 
degrade mainly through bulk erosion, [10, 23-27], however, the gradual size 
change and the images illustrated here suggest that, when encapsulating a 
water soluble drug by a water-in-oil-in-water (W/O/W) emulsion, both surface 
and bulk erosion contribute to the polymer degradation. 
 
Materials and Methods 
To encapsulate a model water soluble drug, a double emulsification, W/O/W, 
was performed. Resomer RG 503H (d,l-lactide glicolide ratio 50/50) was 
obtained from Boehringer Ingelheim, Poly Vinyl Alcohol PVA (MW 25000, 
88% degree of hydrolysis) and sodium chloride from Fisher, Di-
ChloroMethane DCM from Acros and blue dextran 2000 from Pharmacia Fine 
Chemicals. For the release, phosphate buffer solution PBS tablets (Dulbecco 
A) from Oxoid and sodium azide from Sigma Aldrich were used. Reverse 
osmosis water was obtained from a Millipore unit. 
The membrane emulsification apparatus was a dispersion cell provided by 
Micropore Technologies Ltd, Leicestershire, UK. The discontinuous phase 
was injected by a syringe pump at the base of the cell; it passed through the 
membrane, where the droplets are formed, into the continuous phase. The 
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continuous phase was agitated by a two-bladed paddle controlled by a DC 
motor. The membrane was a thin flat metal disc with monosized circular pores 
distributed in a highly regular array. Three pore size membranes were used, 
7, 20 and 40 µm in diameter, with the same pore distance equal to 200 µm. A 
more detailed description can be found elsewhere [1-6]. 
 
Particle Production 
This study follows from an earlier one [6], where different solidification 
methods and a variety of operating conditions were considered in order to 
produce the required size of particles and enhance the encapsulation 
efficiency, ε. 
Firstly 2.86 ml of reverse osmosis water, 3000 ppm of blue dextran and 40 (or 
13) g/l of salt were emulsified with 7.14 ml of DCM and different 
concentrations of PLGA (5 to 15%). The emulsification was performed by 
homogenization for thirty minutes (Silverson). This primary emulsion was the 
discontinuous phase for the secondary emulsification. For the second 
emulsification the Dispersion Cell was used. The discontinuous phase was 
injected into 150 ml of reverse osmosis water containing 1% PVA, different 
salt concentrations (40 or 13 g/l) and the water was saturated in DCM. The 
injection rate was 0.5 ml/min, the agitation speed was 600 rpm when a 40 µm 
membrane was used, and 860 rpm for 20 and 7 µm pore sized membranes. 
Once 10 ml of discontinuous phase was injected, the double emulsion was 
poured in to a 400 ml beaker (diameter equal to 8 cm) and magnetically 
stirred overnight at 120 rpm to remove the DCM and form the solidified 
particles.  
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Blue dextran 2000 was chosen as the water-soluble model drug because it 
can be easily measured spectrophotometrically and has been used previously 
for PLGA microparticles [15]. See elsewhere [6] for the development of this 
method. 
 
Particle Characterization 
At the end of the emulsification process, three pictures were taken of the 
newly formed emulsion using an optical microscope. The emulsion droplets 
were not yet solid and they were not stable sufficiently to be analyzed using 
other particle size analysis methods. Up to 1000 droplets were size analyzed 
optically using Image J software. 
After overnight stirring, the droplets became solid particles. Their size and 
size distribution were measured using a Malvern Mastersizer. A comparison 
of Image J and Malvern’s data shows that the two methods provide similar 
results. When FEG-SEM (Carl Zeiss 1530 FEGSEM) pictures were taken, 
some of the particles were placed on a filter paper in a thin layer and left to 
dry overnight. The particles were finally gold coated before obtaining the 
scanning electron micrographs. 
A sample from the outer water phase was filtered using a Whatman filter 
paper number three and analyzed by ultraviolet spectrophotometer at a 
wavelength of 620 nm( UV/VIS Lambda 12, Perkin Elmer) to measure the 
presence of  blue dextran 2000 that was not encapsulated. 
Drug Release Studies 
After the particle characterization analysis the particles were then filtered 
(Whatman filter paper number 3) and washed three times with reverse 
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osmosis water. They were collected, without drying; not to expose them to 
harsh conditions. The particles were carefully equally separated into 10 
samples. 25 ml of PBS and 0.1% sodium azide solution was added to each 
sample. The bottles were sealed and placed in a warm shaking bath at 37 
degrees Celsius and mildly agitated. At regular intervals, one sample was 
taken out of the bath. Pictures of the particles with an optical microscope and 
a FEG-SEM were taken to determine changes in morphology and size. The 
particle size and size distribution was measured by Malvern Mastersizer. The 
release medium was filtered and the presence of blue dextran was detected 
by ultraviolet spectrophotometer at a wavelength of 620 nm. 
 
Results and Discussion 
In the previous work, [6], it was shown how PLGA concentration, membrane 
pore size and osmotic pressure affect particle size and encapsulation 
efficiency. Osmotic pressure was controlled by varying the concentrations of 
salt in the inner and outer water phases during particle production. This work 
reports the use of that information to produce the most suitable particles and 
extends the study of these parameters in to the drug release phase. The 
Dispersion Cell permits the production of a sizeable enough quantity of 
monosized particles so that it is possible to divide in to ten independent 
samples. Usually [19, 21, 24, 28] the release is studied by removing only the 
release medium and replacing it, without disturbing the particles, so as not to 
change their number, or otherwise influence their degradation. In this work, at 
regular intervals, a sample is taken out of the shaking bath and it can be 
completely analyzed. The remaining particles in the other samples continue 
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the release process undisturbed. Hence, following this procedure, it is 
possible to monitor changes in size, size distribution and surface morphology 
of the particles during the release. 
In Table 1, the characteristics of the particles used for the release studies are 
summarized. Different membrane pore diameters were tested in order to 
achieve particles of different sizes. Different PLGA and salt concentrations 
influence the particle morphology. The results are in line with what was 
expected from the previous study [6]. Blank particles (still W/O/W emulsions 
but without blue dextran) were produced to see how the PLGA degradation 
products interfere with the UV measurements. It is possible to see that the 
distribution is narrow for every size produced (span of number distribution 
shown, as defined by the Malvern Mastersizer software) and the 
encapsulation efficiency is typically high. 
Table 1 
Changes in size during release 
In Figure 1 a typical trend of size change during release is presented. The 
D(n,0.5) represents the median size of the number distribution as given by the 
Malvern Mastersizer. Day 0 represents the particles at the end of the 
solidification stage, prior to filtration and separation into samples. 
Figure 1 
A 40 micron pore diameter membrane gives particles of 100 µm diameter, a 
20 µm membrane gives particles in the region of 60 while a 7 µm membrane 
gives particle around 50 µm, see Table 1 for details on size distributions. 
During the release, the particles appear to swell for a period until the polymer 
degradation starts and then the size decreases gradually. Towards the end 
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there are not many particles left and they are not enough for the instrument 
(Malvern Mastersizer) to reach the minimum obscuration level required for 
analysis. Also, because of the change in inner morphology, the refractive 
index, an important parameter in laser light diffraction, was continuously 
changing. Measurements taken from the particle pictures by Image J show 
that the final particle size levels off at around 30 µm. When the particles are 
bigger (obtained by a 40 µm membrane) they reach maximum swelling later 
than the smaller ones, at day 20 rather than day 15 and 13 for 7 and 20 µm 
respectively). Typically, the beginning of the PLGA degradation is around day 
10 [24]. Particles obtained by 20 and 7 µm membranes behave quite similarly 
since they do not differ much in size at the beginning and they reach 
maximum swelling in the same period. Also, for the 40 µm membrane 
particles, there appears to be a lag time before the size starts increasing. The 
particle size is related to the surface area-volume ratio. A small size leads to a 
higher ratio, hence a quicker hydration of the particles surrounded by the 
water medium and the swelling process starts immediately. With the smaller 
size, the acidic pH required to accelerate the degradation process is reached 
quicker. The acid being generated by the degradation process itself. 
 
This change in size pattern during release is typical of particles encapsulating 
a water phase. Simple particles, e.g. obtained by a single emulsification, were 
also produced. This kind of particle would be suitable for oil soluble drugs. An 
oil phase made of PLGA and DCM was injected in the continuous phase 
(usual combination of PVA, salt and DCM) under the same conditions of when 
water encapsulating droplets are produced. They also underwent solidification 
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and release studies following the same procedures. In Figure 2, the change in 
size of these particles is shown and compared with the double emulsification 
ones.  
Figure 2 
While particles obtained by a double emulsification swell up to a maximum 
and then their size decreases due to PLGA degradation, particles that do not 
encapsulate a water phase grow in size until losing their structure, see also 
the later optical images. 
 
Following from the earlier study [6], the inner water phase contains a salt 
concentration of 40 g/l. The swelling was thought to be due to this inner salt 
causing an osmotic pressure between the inner water phase and the release 
water medium made of PBS. Salt was added to the latter to suppress the 
swelling. It is difficult to exactly balance the salt concentration during the 
release. Salt (NaCl) is already present in the PBS solution (8 g/l) together with 
other salts (KCl, Na2HPO4, KH2PO4).  The initial inner concentration is known 
(40 g/l) but during the solidification itself there is water intake. Since the drug 
release presents a lag time corresponding to the swelling period, suppressing 
the swelling should help avoid the lag time period. The results from this set of 
experiments were not conclusive (data not shown), in some cases swelling 
was still visible and they all presented a lag time in the  model-drug release. 
As a result, the inner salt concentration during production was lowered to 13 
g/l and no salt was added to the PBS solution, to better mimic body conditions 
and lower the swelling, assuming it was due to the presence of an osmotic 
pressure. 
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In Figure 3, the effect of the inner salt concentration during production, on the 
change in size during release, is shown. The filled markers represent particles 
obtained with 13 g/l of salt in the inner and outer water phase. The empty 
ones are for when 40 g/l was used in both water phases. In both case, there 
was no osmotic pressure during the production phase, a 40 µm membrane 
was used and 15% PLGA. The particles were then dissolved in the same 
release medium. The starting size is the same, as all the conditions 
influencing the size are equal. The size change pattern is similar and, 
surprisingly, a lower amount of salt in the inner water phase leads to a higher 
volume swelling. It shows that swelling is not only due to osmotic pressure, 
due to the difference in salt concentration between the inner water phase and 
the PBS solution, but there must be other driving forces. Some papers report 
the intake of water due to osmotic pressure created by the degradation 
products [27]. 
Figure 3 
The remaining aspect to consider is the PLGA concentration and the effect of 
osmotic pressure, Figure 4. The diamonds represent particles obtained using 
15% of PLGA while the triangles are for 5% PLGA. Using the same pore 
diameter membrane, 40 µm, two sizes are obtained by creating an inward flux 
of water due to the osmotic pressure during the solidification, see [6]. Once 
the particles are placed in the same release medium, the only effect of 
osmotic pressure left is a different particle structure and morphology. 
Comparing the grey and white diamonds in Figure 4, the initial size is 
different, as expected, but they follow the same size change pattern during 
the release. When using 5% PLGA, there was not any lag time before the size 
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started increasing, the maximum swelling was lower and the size decreased 
once degradation started and it was more gradual. A lower amount of polymer 
provides a less dense texture and the particles are, therefore, more porous. 
The particles become thoroughly hydrated and the swelling starts 
immediately, as would be expected for smaller particles. At the same time, a 
more porous structure allows the polymer degradation products to diffuse out 
more easily, lowering the acidic pH environment inside the particles and 
slowing down the degradation process. Hence, a slower decrease in size 
once the particles are degrading. More studies are needed to link different 
degradation behaviours with the cumulative drug release. 
Figure 4 
Cumulative Drug Release 
Together with all the data presented for the change in size, data regarding the 
cumulative blue dextran release was collected. The data shown here gives 
useful information about the general behaviour, but lacks the fine precision of 
the particle size data. In Figure 5 the cumulative release from particles 
obtained with the three membrane sizes, 15% PLGA and no osmotic pressure 
are shown. The dotted lines help to visualize the trend. The drug release 
pattern follows the usual three phases: initial burst followed by a lag time and 
a following release up to completion. The lag time seems to match the period 
of particle swelling. A release medium influx would appear to act against the 
drug outward flux.  
Figure 5 
For the mathematical modelling, because of the UV instrument properties and 
the results obtained from the study of the blank particles, measurements 
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below 10 ppm are not reliable. This leads to the exclusion of the data below 
30% of cumulative release, which corresponds to the period of burst and lag 
time. Discussing only the results above the limit of 30%, it is evident that 
smaller particles reach total release quicker than bigger particles. This is to be 
expected [20, 29], but it has been questioned previously [30]. The reported 
effects in the literature of particle size on the release are various and 
contrasting. Some say that the lower surface area-volume ratio (bigger 
particle diameter) leads to a build up of acidic products inside the particle 
hence a quicker degradation and release. At the same time, in the bigger 
particles, the drug is distributed closer to the outer surface and the drug 
loading is higher, increasing the apparent drug diffusivity. On the other hand, 
if the release is diffusion controlled, higher particle diameter should result in 
slower release. 
 
Model 
There have been several studies modelling the release. The first part of 
release is commonly considered diffusion controlled [25, 26, 31-33]. Also, in 
[34], it was shown that if the drug is water soluble, the release from erodible 
tablets follows primarily a swelling-controlled diffusion process. Most of the 
previous studies consider a variation of the diffusivity coefficient rather than 
the variation of particle size. As the degradation proceeds, the molecular 
weight decreases and the diffusivity coefficient increases, employing a bulk 
erosion system [31-33]. In the work reported here, the gradual change in size 
and particle morphology, see below, seems to suggest the co-existence of a 
surface erosion activity. The information about the changes in size during 
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release generates two possible approaches for the modelling of the 
degradation phase. Firstly, it is possible to couple a diffusion based model for 
the first part with a shrinking core model for the release during the 
degradation of the particles. Another option is to consider the change in size 
of the particles both during the swelling and during the shrinking due to 
degradation, using in both cases a diffusion equation with a constant 
diffusivity. 
For the diffusion based model the equations used are: 
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where: 
q is the concentration of blue dextran expressed as grams of blue dextran 
encapsulated divided by grams of total particle, 0.008 corresponds to 3000 
ppm of blue in the initial inner water phase. For each set of data the 
encapsulation efficiency is considered, so the boundary conditions are not 
going to be 0.008, but lower and different for each situation: according to the 
encapsulation efficiency. Deff is the effective diffusion coefficient, initially 1e-15 
cm2/s, but then altered iteratively to improve the data-model agreement, R is 
the radius of the particle, Vrel is the volume of release medium, b is the 
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average concentration of blue inside the particle, mb is the mass of blue found 
in the PBS solution. R is expressed as an equation to consider the change in 
size. The particle radius in cm was plotted against the time of release in 
seconds; a linear trend line was considered by splitting the process in to two: 
swelling and degradation. The system was solved by using the software 
PDESOL (Numerica, USA), running on an XP operating system on a PC. 
When considering a shrinking core based model for the second part of 
release the following equations were used: 
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where: 
Dshr.core is the coefficient of diffusivity which best fits in this situation: 1e-13 
cm2/s, c* is the inner initial concentration of blue dextran, ρp is the density of 
the particle, taken as the density of PLGA, q is the same blue concentration 
as expressed for the diffusion model, N is the number of particles, mb(0) is the 
amount in grams of blue dextran inside the particle at time 0, mbin is the 
amount of blue dextran inside the particle changing with time. 
Figure 6 
Figure 6 shows a reasonable model-experimental data matching. The data 
refers to particles obtained with a 20 µm membrane, the diamonds are the 
experimental data and the continuous line is the model based on diffusion 
during the initial swelling period. Once degradation starts, the two approaches 
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are compared: the line-dot curve represents the shrinking core model whilst 
the dotted line uses the diffusion model with the radius decreasing over time. 
It looks like the latter best represents the results. The shrinking core model 
cannot be used over periods of long release since the second part of equation 
5 can become higher than the previous, leading to a negative square root. 
Thus, a diffusion based approach including the variation in size, seems to 
better represent the experimental data.  
 
Images 
For every sample, pictures with an optical microscope were taken to confirm 
the sizes measured by the Malvern and track any visible change. Pictures of 
particles obtained by a 20 µm membrane, as an example, are shown. At day 
zero the particles look dark, spherical and monosized, Figure 7. 
Figure 7 
Figure 8 
Figure 9 
 
The dark colour is not due to the blue dye encapsulated since the blank 
particles look the same, Figure 10. The dark colour is due to the internal 
emulsion. The primary emulsification was obtained by a homogenizer, which 
generates very small droplets. As the release progresses, it is possible to see 
some changes, Figure 8 at day 13 and Figure 9 after 30 days.  
At day 13 both the particles obtained with 7 and 20 µm have already achieved 
their maximum swelling and degradation is starting, see also Figure 1. At day 
31, Figure 9, the particles have already achieved complete release. They 
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have become almost transparent, an internal boundary is visible. It may be 
the front of the internal degradation (bulk erosion), or thinning of the particle 
wall. These particles are very weak and they did not stand the drying and 
coating conditions used to obtain images using the FEG-SEM technique. 
In bulk erosion, the expected size of the microsphere is almost constant, and 
the external fluid penetrates into the microsphere throughout and, thefore, 
internal erosion of the polymer takes place everywhere. In the surface erosion 
of a microsphere model, the erosion of the polymer is largely confined to the 
external boundary which causes the size of the microsphere to decrease 
gradually [35, 36].  
PLGA degradation is an autocatalytic hydrolysis reaction. The acidic 
environment created by the degradation products speed up the reaction itself. 
The majority of studies consider oil-soluble, or solid drugs, and they perform a 
single emulsification. There is no water phase inside. Once in the release 
water medium, the porous particles take up water, the inner pH decreases 
and the degradation starts. Because of the polymer matrix the products 
cannot diffuse out easily and the bulk area becomes more and more acidic. 
The outer surface is kept neutral by the buffer, resulting in mainly bulk erosion 
[27]. However, when a double emulsification is performed, a water phase is 
present inside the particles. This water phase acts in two ways: to initiate the 
hydrolysis reaction but also to mildly buffer the acidity of the products 
generated. The bulk degradation is, therefore, slower and it is possible to 
notice an effect on the surface degradation too. The inner water buffer effect 
is shown by the fact that PLGA degradation starts slightly later than previously 
reported, day 11 to 20 instead of 10 [24]. The images show the effects of 
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surface degradation. In [23] the authors saw PLA and PLGA surface erosion 
when the degradation was conducted in a basic environment. 
In Figure 10 particles made by a double emulsification, but without dye 
(referred as blank), and particles obtained by single emulsification (referred to 
as simple) are shown.  
Figure 10 
Figure 11 
 
Despite missing the blue dye, the blank particles are dark due to the inner 
structure obtained by the primary emulsification performed by a homogenizer, 
Figure 10a. At day 0, particles obtained by single emulsification look clear, 
Figure 10b. In Figure 10c and d images were taken with the FEG-SEM 
technique of the same particles and are shown to highlight the difference in 
morphology caused by the presence of the inner water phase. 
Following the change in size of the simple particles, as shown in Figure 2, the 
inner morphology changes due to bulk erosion and it becomes progressively 
darker, see Figure 11. The particles become very weak and they fuse 
together, in agreement with the size data shown in Figure 2. 
 
Conclusions 
Membrane emulsification, using a laminar sheet membrane in a Dispersion 
Cell, provides a tool to obtain monosized and size controlled emulsions and 
particles. Varying the production parameters, it is possible to achieve high 
encapsulation efficiency and influence the internal porosity. Due to the 
significant amount of particles produced by this technique it was possible to 
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study the change in size, surface morphology and drug cumulative release of 
the resulting particles over a prolonged period of time. The particles go 
through a period of swelling and water intake, corresponding to the initial burst 
and lag time of the drug release. Then degradation prevails and the size 
gradually decreases, liberating more encapsulated drug until completion. 
Modelling by a shrinking core approach was not successful, with poor 
agreement between model and data. However, a model based on diffusion, 
and considering the particle change in size, has been shown to follow the 
experimental data in reasonable agreement. The images and the size change 
data suggests that, together with bulk erosion, when an external water phase 
is present, surface erosion contributes significantly to the PLGA degradation.  
In this study, bulk degradation may well have been suppressed by the 
buffering influence of the internal water phase, reducing the acid 
concentration of the PLGA degradation products.  
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Table 2   Conditions and characterization of produced particles 
Membrane 
pore 
diameter 
μm 
Inner 
salt 
conc 
g/l 
Outer 
salt 
conc 
g/l 
Salt 
ratio 
PLGA 
conc 
 
% 
Median 
particle 
size 
μm 
span Encapsulation 
efficiency 
 
% 
40 40 40 1 15 91 0.599 84 
   1 15 86 0.437 blank 
   1 5 85 0.533 85 
   1 5 81 0.605 blank 
 40 13 1/3 15 117 0.609 74 
   1/3 5 111 0.583 30 
 13 13 1 15 95 0.669 61 
20 40 40 1 15 36 0.881 95 
 40 13 1/3 15 61 1.300 88 
 13 13 1 15 49 0.643 72 
7 13 13 1 15 41 0.630 87 
   1 15 37 0.449 blank 
 
 25
List of Figure captions 
Figure 1 Change in size during the release of particles obtained with 
different membrane pore size: 
40 µm 20 µm 7 µm 7 µm repeat 
 
Figure 2 Change in size during release of particle obtained by a 7 µm 
membrane, encapsulating a water phase (W/O/W) or obtained 
by a single emulsification (O/W) 
W/O/W O/W 
 
Figure 3 Effect of inner salt concentration on the particle size during  
  release 
13 g/l 40 g/l 
 
Figure 4 Effect of PLGA concentration and osmotic pressure during 
particle production on the change in size during release 
15%, 1/3 15%, 1/1 5%, 1/3 15%, 1/1 
 
Figure 5 Cumulative drug release from particles of different sizes, 
obtained by different membrane pore sizes: 
40 µm 20 µm 7 µm 
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Figure 6 Comparison between data and model prediction for the release 
from particles obtained with a 20 µm membrane 
experimental data diffusion swelling 
diffusion degradation shrinking core 
 
Figure 7 Images obtained by optical microscope at the end of the 
solidification phase. In the left column the bar indicates 100 µm, 
while in the right column the bar indicates 50 µm. 
 
Figure 8 Images of the releasing particles at day 13 
 
Figure 9 Images of the releasing particles at day 31 
 
Figure 10 Particles obtained by a 7 µm membrane, a) and c) performing a 
double emulsion but without blue dye in the water phase (blank) 
and b) and d) by single emulsification to encapsulate a 
hydrophobic drug (simple) 
 
Figure 11 Change in morphology during release of particles obtained by 
single emulsification 
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Figure 1 Change in size during the release of particles obtained with 
different membrane pore size: 
40 µm 20 µm 7 µm 7 µm repeat 
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Figure 2 Change in size during release of particle obtained by a 7 µm 
membrane, encapsulating a water phase (W/O/W) or obtained 
by a single emulsification (O/W) 
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Figure 3 Effect of inner salt concentration on the particle size during  
  release 
13 g/l 40 g/l 
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Figure 4 Effect of PLGA concentration and osmotic pressure during 
particle production on the change in size during release 
15%, 1/3 15%, 1/1 5%, 1/3 15%, 1/1 
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Figure 5 Cumulative drug release from particles of different sizes, 
obtained by different membrane pore sizes: 
40 µm 20 µm 7 µm 
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Figure 6 Comparison between data and model prediction for the release 
from particles obtained with a 20 µm membrane 
experimental data diffusion swelling 
diffusion degradation shrinking core 
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day 0 
  
 
 
 
Figure 7 Images obtained by optical microscope at the end of the 
solidification phase. In the left column the bar indicates 100 µm, 
while in the right column the bar indicates 50 µm. 
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day 13 
 
 
 
Figure 8 images of the releasing particles at day 13 
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day 31 
  
 
 
Figure 9 images of the releasing particles at day 31 
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a b 
  
c d 
 
 
 
Figure 10 Particles obtained by a 7 µm membrane, a) and c) performing a 
double emulsion but without blue dye in the water phase (blank) 
and b) and d) by single emulsification to encapsulate a 
hydrophobic drug (simple) 
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a) day 19 b) day 31 
 
 
 
Figure 11 Change in morphology during release of particles obtained by 
single emulsification 
 
 
 
 
